Ancient Viral DNA Builds Embryos, and Cancer Steals the Trick

Roughly one week into your own development, when you were a tiny ball of about a hundred cells, a fossil virus was quietly keeping you alive. Not a live infection - a remnant of one, stitched into the genome millions of years ago. New research shows that this piece of ancient viral DNA is essential for the earliest stages of human embryo development, and that cancer cells have learned to flip the very same switch to stay young. The work, as reported by MedicalXpress, appears in the journal Science Advances.

The finding comes from the Francis Crick Institute in London, where immunologist George Kassiotis and his team spent years puzzling over a strange observation. A few years ago, they discovered that some lung tumors produce an unusual version of calbindin, a protein that buffers calcium inside cells. Calcium becomes toxic at high levels, and calbindin mops it up, which is why the protein is normally found where calcium control is critical, like the brain and kidneys. In the tumors, though, the protein was being switched on by a stretch of ancient viral DNA: a human endogenous retrovirus named HERVH. The odd part was that tumor cells using this switch resisted cellular aging, staying flexible in a way that recalled early embryonic cells. A commentary from the Max Delbrück Center later described the same mechanism as a textbook case of an ancient retrovirus being repurposed by tumors.

To find out why a cancer-boosting switch existed at all, postdoctoral researcher Judith Pape - working with colleagues who pioneered gene editing in human embryos - removed the HERVH switch from human embryonic stem cells. Without it, the cells could not make the special form of calbindin, and they faltered: they grew poorly or committed to a single cell type prematurely, according to the study authors. In lab-grown blastoids, stem-cell models that mimic the blastocyst stage, deleting the switch meant the structures could not form properly, suggesting the fossil helps a real blastocyst develop and prepare for implantation. A third model, amnioids that mimic the developing amniotic sac, showed the same dependence: without the ancient viral DNA, some failed to form a sac-like structure at all.

How ancient viral DNA ended up in your genome

Retroviruses copy themselves into the DNA of the cells they infect. When that happens in a cell destined to become sperm or eggs, the copy turns heritable. Most of these fossils accumulate mutations and fall silent, which is why roughly eight percent of your genome is debris left behind by ancient viral DNA with no obvious job. But this particular HERVH element slipped in after the ancestors of humans and other great apes split from orangutans, about thirteen million years ago, and calbindin began appearing in the preimplantation embryo at exactly the same moment in evolutionary history. Coincidence looks unlikely. Kassiotis framed the swap as evolution "making a trade," according to the institute's account of the work: a chance infection supplied the calcium-management instruction carried by ancient viral DNA, which outperformed the older one, and the old instruction was discarded.

The catch: cancer found the switch too

The tradeoff is real. In a small fraction of people, tumor cells reactivate the same ancient viral DNA program - calcium buffering that holds off cellular aging and lets cells keep their options open. In a young embryo, that flexibility is healthy; in a tumor, it is dangerous. The reassuring detail is that the hijacked version of the protein is molecularly distinct from the calbindin doing critical work in the brain and kidneys. That difference matters because it raises the possibility of a drug that blocks only the tumor form, stopping cancer from borrowing the embryo's ancient viral DNA trick while the normal protein keeps doing its job. Kassiotis is clear that such a treatment is years away, but the target is unusually clean as cancer targets go.

What it could mean for fertility treatment

Separately, the team thinks HERVH-calbindin could become a marker of embryo health in IVF. Embryos carrying the active switch formed more efficiently in the lab, so screening for it might one day help clinics select embryos most likely to develop. Both applications carry the same caveat: blastoids and amnioids are sophisticated models, not real embryos, and a fertility test or a drug built around ancient viral DNA remains a research-stage idea. Still, the direction is striking - the most promising new targets in oncology may be the ones our own development used first, and the best new fertility markers may be hiding in DNA once dismissed as junk.

Zoom out, and the study is another crack in the idea that most of the genome is dead weight. Old infections did not just leave scars; they left tools. The syncytin genes that build the placenta came from retroviruses, and now a viral switch joins the machinery of the embryo's first days. The pattern keeps repeating: pieces of ancient viral DNA show up exactly when cells need to be plastic and resilient. Learning to tell the embryo's use of them from the tumor's is the next chapter of this research. For more science explained at this depth, browse the deep dives topic page, and read how one cancer drug fooled its own designers.